Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
30.94 USD | -4.83% | -2.95% | +132.63% |
May. 23 | Dyne Therapeutics Insider Sold Shares Worth $1,002,751, According to a Recent SEC Filing | MT |
May. 22 | Dyne Therapeutics Prices $325.5 Million Common Stock Offering | MT |
Evolution of the average Target Price on Dyne Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Dyne Therapeutics, Inc.
Chardan Research | |
HC Wainwright | |
Morgan Stanley | |
Stifel Nicolaus | |
Piper Sandler | |
Oppenheimer | |
Raymond James | |
Guggenheim | |
JPMorgan Chase |
EPS Revisions
- Stock Market
- Equities
- DYN Stock
- Consensus Dyne Therapeutics, Inc.